Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Neuroimmunomodulation. 2014 Oct 3;22(3):203–212. doi: 10.1159/000364912

Figure 1. Clinical parameters of TNBS-induced colitis are milder in VIP KO mice compared to WT mice.

Figure 1

TNBS (5 mg) in 50% EtOH was intracolonically administered to 6-8 week-old WT and VIP KO mice. The results shown are a combination of five experiments for a total of n=14 for each group of vehicle-treated mice (50% EtOH), n=40 for TNBS –treated WT mice and n=38 for VIP KO mice. Mice were weighed every day for four days and colitis was scored from 0 to 4 as described in the Material and Methods section with 0 being no colitis and 4 severe colitis. A) represents % of original weight, B) represents the difference of weight between each TNBS-treated group and their respective EtOH-treated control group as percentage of original weight, and C) represents the colitis score. VIP KO mice exhibited significantly reduced weight loss and colitis compared to WT mice. Student's t-test *p<0.05, ***p<0.001.